Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

Third Phase II Trial Initiated by Myriad For Azixa(TM)

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported on new clinical advancements for Azixa(TM)* (MPC-6827), a vascular disrupting agent licensed by the Company to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Myriad announced yesterday that it has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to assess Azixa's safety profile and the extent to which it can improve the overall survival of these patients. Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain.

"We are pleased at the clinical advancement Myriad has reported on Azixa, and view it as further evidence of the commercial potential of the compound," stated Jack Talley, President and Chief Executive Officer. "We believe that the study of Azixa in this new indication affords EpiCept with an expanded opportunity to capitalize on the financial benefits associated with our agreement with Myriad, including milestone payments, sublicensing income and potentially future royalties if Azixa continues to progress successfully."

Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad in 2003. The agreement requires that Myriad make future licensing, research and milestone payments to EpiCept, as well as pay a portion of any sublicensing income and pay a royalty on product sales. EpiCept will earn a milestone payment upon the dosing of the first patient in a Phas
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2008)... HILDEN, Germany, May 21 /...V Test as Front-line,Screen, Long-term data from ...Cancer show that women screened only with a human ...o develop moderate to severe cervical disease over...onal cytology (the Pap,"smear"). The research foll...
(Date:5/20/2008)...Statistically Significant Reduction of IBS Pain an...Effect Observed, SAN DIEGO, May 20 /...results of a recent Phase 2b study of its oral kap...onstrated statistically significant,results in the...adoline,produced significant improvement in diarrh...
(Date:5/20/2008)... 94 Percent of Men Maintained Normal Testosteron...Treatment 92 Percent of Men Expressed Sat...- Indevus,Pharmaceuticals, ... NEBIDO(R),(testosterone undecanoate), an investig...he treatment of hypogonadism, was presented in a l...
(Date:5/20/2008)...ata on Newly-Approved Cimzia(R) Presented at Diges...swire/ -- UCB announced today that data,presented ...sustainable,efficacy and safety of Cimzia(R) (cert...ts with moderate to severe Crohn,s disease. Data a...y of responders and the remission,rate remained st...
Breaking Medicine Technology:Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 2Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 3Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 4Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 2Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 3Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 4Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 2Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 3Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 4Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 2Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 3Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 4Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 5Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 6Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 7Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 8BLU MED Announces New Medical Preparedness Contracts 7283 1BLU MED Announces New Medical Preparedness Contracts 7283 2BioSpace Launches 2nd Edition of Southern Pharm 28TM 29 Hotbed Campaign 2027 1BioSpace Launches 2nd Edition of Southern Pharm 28TM 29 Hotbed Campaign 2027 2U S Patent 7 299 083 Awarded to Signalife 2023 1U S Patent 7 299 083 Awarded to Signalife 2023 2FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 1FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 2FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 3FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 4
...uture Pandemics , ,BETHESDA, Md., April 2, 2007--O...anish influenza pandemic is why it struck differen...cipalities such as,St. Louis spared the fate of th...emented similar public health measures? What made ...es funded by the,National Institutes of Health (NI...
...ent Therapy Significantly,Improved Absorption of F...y and DAYTON, Ohio, April 04, 2007 /PRNewswire/ --..., today unveiled,data from two phase III clinical ... formerly EUR-1008, for the treatment of,Exocrine ...ug,Administration (FDA) granted fast track status ...
Other Medicine Technology:Rapid Response was Crucial to Containing the 1918 Flu Pandemic 2Rapid Response was Crucial to Containing the 1918 Flu Pandemic 3Rapid Response was Crucial to Containing the 1918 Flu Pandemic 4Rapid Response was Crucial to Containing the 1918 Flu Pandemic 5Eurand Announces Positive Phase III Clinical Study Results 2Eurand Announces Positive Phase III Clinical Study Results 3Eurand Announces Positive Phase III Clinical Study Results 4Eurand Announces Positive Phase III Clinical Study Results 5
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
...f contagious skin infections, the threat of pandem...oap and Detergent Association (SDA) to issue its s...a “C-minus”, a downgrade from 2004, when the count...nt than ever that people understand that clean han...
...eptember issue of Mayo Clinic Proceedings says tha..., all intravascular devices (IVDs) have an inheren...dult patients. An IVD is any device that allows ac...ter is the most commonly used device. As many as 5...
...called enzymes catalyze specific biochemical react...mic fluctuations//protein conformation or structur...recent findings reveal that it is the "dynamic ene... specific pathway that reduces the number and dime...
...d on Monday at a local hospital in Tulungagung, Ea...Health Ministry officials confirmed yesterday.// R...information center told Reuters that the boy had c...ts confirmed that he died to H5N1 virus infection....
Other Medicine News:Health News:America’s Clean Hands Report Card - Can’t Rise Above ‘C’ L 2Health News:America’s Clean Hands Report Card - Can’t Rise Above ‘C’ L 3Health News:Infection Risk High With All IVDs 2Health News:"Dynamic Energy Landscape" of enzyme in Catalysis 2
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety.
The 5500s electronic architecture incorporates advanced circuit designs optimized for efficiency and function. We call it HI VUE an engineering philosophy that directs the development of each subsys
The HI VISION 6500 high resolution digital ultrasound system offers advanced clinical imaging, enhanced operating efficiency, and remarkable clinical flexibility, all in robust and versatile configur
...features of the ELECTRA 1400C are designed to achi...away capabilities. This system includes automated ...nogen and factor assays in a single setup. It also...eparation of reference curves and patient sample d...
Medicine Products: